Original Literature | Model OverView |
---|---|
Publication
Title
Cellular reprogramming by gram-positive bacterial components: a review.
Affiliation
Department of Academic Surgery, Cork University Hospital, National University ofIreland/University College Cork, Wilton, Cork, Ireland.
Abstract
LPS tolerance has been the focus of extensive scientific and clinical researchover the last several decades in an attempt to elucidate the sequence of changesthat occur at a molecular level in tolerized cells. Tolerance to components ofgram-positive bacterial cell walls such as bacterial lipoprotein andlipoteichoic acid is a much lesser studied, although equally important,phenomenon. This review will focus on cellular reprogramming by gram-positivebacterial components and examines the alterations in cell surface receptorexpression, changes in intracellular signaling, gene expression and cytokineproduction, and the phenomenon of cross-tolerance.
PMID
16885502
|
Entity
NF-kappaB
--
MO000000058
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m46
10
infinite
0
TRANSPATH | MO000000058 |
--
TRAF6
--
MO000000212
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m183
10
infinite
0
InterPro | IPR001841 |
TRANSPATH | MO000000212 |
--
AP-1
--
MO000000276
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m219
10
infinite
0
TRANSPATH | MO000000276 |
--
TNF-alpha
--
MO000000289
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m230
10
infinite
0
InterPro | IPR003636 |
TRANSPATH | MO000000289 |
--
IRAK-M
--
MO000016569
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1571
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000016569 |
--
TLR2
--
MO000019397
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m3964
10
infinite
0
InterPro | IPR000157 |
TRANSPATH | MO000019397 |
--
IRAK-4
--
MO000039077
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m17258
10
infinite
0
TRANSPATH | MO000039077 |
--
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0
infinite
0
--
--
e10
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m10
0
infinite
0
--
LPS:CD14
--
e11
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m11
0
infinite
0
--
BLP
--
e12
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m12
0
infinite
0
--
BLP:CD14
--
e13
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m13
0
infinite
0
--
csml-variable:Double
m14
0
infinite
0
--
LTA:CD14
--
e15
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m15
0
infinite
0
--
LPS:TLR4
--
e16
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m16
0
infinite
0
--
LPS:TLR4:MYD88
--
e17
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m17
0
infinite
0
--
LPS:TLR4:MYD88:IRAK
--
e18
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
csml-variable:Double
m18
0
infinite
0
--
LPS:TLR4:MYD88:IRAK:TRAF6
--
e19
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m19
0
infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0
infinite
0
--
NF-kappaB:IkappaB
--
e21
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m21
0
infinite
0
--
AP-1{active}
--
e26
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m29
10
infinite
0
TRANSPATH | MO000000276 |
--
csml-variable:Double
m30
0
infinite
0
--
TLR2:LAM
--
e28
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m31
0
infinite
0
--
STF
--
e29
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m32
0
infinite
0
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0
infinite
0
--
STF:TLR2
--
e30
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m33
0
infinite
0
--
csml-variable:Double
m34
0
infinite
0
--
LPS:TLR4:MYD88:IRAK1:TRAF6
--
e32
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m35
0
infinite
0
--
IRAK2:TRAF6
--
e33
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m36
0
infinite
0
--
IRAK4:TRAF6
--
e34
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m37
0
infinite
0
--
IRAKM:TRAF6
--
e35
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m38
0
infinite
0
--
IRAK1:TRAF6
--
e36
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m39
0
infinite
0
--
protein remnants
--
e37
cso30:c:EntityBiological
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m40
0
infinite
0
--
LPS:TLR4:MYD88:IRAK1
--
e38
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m41
0
infinite
0
--
LPS:TLR4:MYD88:IRAK1{p}:TRAF6
--
e39
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m42
0
infinite
0
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0
infinite
0
--
LPS:TLR4:MYD88
--
e40
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m43
0
infinite
0
--
IRAK1:TRAF6:TAK1:TAB2
--
e41
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m44
0
infinite
0
--
NF-kappaB:IkappaB{p}
--
e42
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m22
0
infinite
0
--
NF-kappaB:IkappaB{p}{ub}
--
e43
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m45
0
infinite
0
--
MALP2
--
e5
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m5
0
infinite
0
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0
infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0
infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0
infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0
infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0
infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0
infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0
infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0
infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0
infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0
infinite
0
--
TLR2:MALP2
--
e6
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m6
0
infinite
0
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0
infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0
infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0
infinite
0
--
--
e7
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m7
0
infinite
0
--
--
e8
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m8
0
infinite
0
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0
infinite
0
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c1 : 1
stoichiometry:c2 : 1
stoichiometry:c3 : 1
m3964*m5*0.1
nodelay
--
0
PMID: 16885502 MALP-2 was found to induce self-tolerance as measured by TNF-{alpha} production but also, to induce cross-tolerance to LPS.
p10
p10
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c28 : 1
stoichiometry:c29 : 1
stoichiometry:c89 : 1
stoichiometry:c30 : 1
m18*m183*0.1
nodelay
--
0
PMID: 16885502, 10754329, 10215628 After ligand binding, TLRs sequentially recruit the adaptor molecules MyD88, IL-1R-associated kinase (IRAK)and TNF receptor-associated factor 6 (TRAF6). PMID: 16885502 IRAK-M prevents dissociation of IRAK-1 and IRAK-4 from MyD88 and inhibits formation of the IRAK-TRAF-6 complex.
p11
p11
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c90 : 1
stoichiometry:c91 : 1
stoichiometry:c108 : 1
stoichiometry:c92 : 1
m34*m17*0.1
nodelay
--
0
PMID: 16885502, 10754329, 10215628 After ligand binding, TLRs sequentially recruit the adaptor molecules MyD88, IL-1R-associated kinase (IRAK)and TNF receptor-associated factor 6 (TRAF6). PMID: 16885502 IRAK-M prevents dissociation of IRAK-1 and IRAK-4 from MyD88 and inhibits formation of the IRAK-TRAF-6 complex.
p12
p12
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c31 : 1
stoichiometry:c36 : 1
stoichiometry:c32 : 1
m207*m44*0.1
nodelay
--
0
PMID: 16885502 TAK-1 phosphorylates the MAPKs and the IKK complex, a cytoplasmic inhibitor of NF-{kappa}B
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c33 : 1
stoichiometry:c35 : 1
stoichiometry:c34 : 1
m21*m20*0.1
nodelay
--
0
PMID: 16885502, 10602462 Activation of IKK complex results in phosphorylation of I{kappa}B{alpha} and I{kappa}Bbeta, ubiquitination, and degradation of I{kappa}B, and release of the active NF-{kappa}B complex.
p14
p14
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c37 : 1
stoichiometry:c39 : 1
stoichiometry:c38 : 1
m23*m44*0.1
nodelay
--
0
PMID: 16885502 TAK-1 phosphorylates the MAPKs and the IKK complex, a cytoplasmic inhibitor of NF-{kappa}B. PMID: 16885502, 11303728 Three major MAPKs, ERK1/2, JNK, and p38, are phosphorylated and activated following LPS stimulation.
p15
p15
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c40 : 1
stoichiometry:c103 : 1
stoichiometry:c41 : 1
m25*m44*0.1
nodelay
--
0
PMID: 16885502 TAK-1 phosphorylates the MAPKs and the IKK complex, a cytoplasmic inhibitor of NF-{kappa}B. PMID: 16885502, 11303728 Three major MAPKs, ERK1/2, JNK, and p38, are phosphorylated and activated following LPS stimulation.
p16
p16
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c43 : 1
stoichiometry:c105 : 1
stoichiometry:c44 : 1
m549*m44*0.1
nodelay
--
0
PMID: 16885502 TAK-1 phosphorylates the MAPKs and the IKK complex, a cytoplasmic inhibitor of NF-{kappa}B. PMID: 16885502, 11303728 Three major MAPKs, ERK1/2, JNK, and p38, are phosphorylated and activated following LPS stimulation.
p17
p17
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c45 : 1
stoichiometry:c104 : 1
stoichiometry:c46 : 1
m554*m44*0.1
nodelay
--
0
PMID: 16885502 TAK-1 phosphorylates the MAPKs and the IKK complex, a cytoplasmic inhibitor of NF-{kappa}B. PMID: 16885502, 11303728 Three major MAPKs, ERK1/2, JNK, and p38, are phosphorylated and activated following LPS stimulation.
p18
p18
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c49 : 1
stoichiometry:c51 : 1
stoichiometry:c50 : 1
m219*m27*0.1
nodelay
--
0
PMID: 16885502, 11357875 In turn, these adaptor molecules activate the I{kappa}B kinase (IKK) complex and MAPKs, JNK, p38, and ERK1/2, leading to the activation of NF-{kappa}B and AP-1, respectively, and ultimately, to transcription of inflammatory target genes.
p19
p19
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c52 : 1
stoichiometry:c54 : 1
stoichiometry:c53 : 1
m219*m24*0.1
nodelay
--
0
PMID: 16885502, 11357875 In turn, these adaptor molecules activate the I{kappa}B kinase (IKK) complex and MAPKs, JNK, p38, and ERK1/2, leading to the activation of NF-{kappa}B and AP-1, respectively, and ultimately, to transcription of inflammatory target genes.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c5 : 1
stoichiometry:c4 : 1
m6*0.1
nodelay
--
0
PMID: 16885502 MALP-2 was found to induce self-tolerance as measured by TNF-{alpha} production but also, to induce cross-tolerance to LPS.
p20
p20
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c55 : 1
stoichiometry:c57 : 1
stoichiometry:c56 : 1
m219*m26*0.1
nodelay
--
0
PMID: 16885502, 11357875 In turn, these adaptor molecules activate the I{kappa}B kinase (IKK) complex and MAPKs, JNK, p38, and ERK1/2, leading to the activation of NF-{kappa}B and AP-1, respectively, and ultimately, to transcription of inflammatory target genes.
p21
p21
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c58 : 1
stoichiometry:c60 : 1
stoichiometry:c59 : 1
m219*m28*0.1
nodelay
--
0
PMID: 16885502, 11357875 In turn, these adaptor molecules activate the I{kappa}B kinase (IKK) complex and MAPKs, JNK, p38, and ERK1/2, leading to the activation of NF-{kappa}B and AP-1, respectively, and ultimately, to transcription of inflammatory target genes.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c61 : 1
stoichiometry:c62 : 1
stoichiometry:c63 : 1
m3964*m30*0.1
nodelay
--
0
PMID: 16885502 The mycobacterial components, lipoarabinomannan (LAM) and soluble tuberculosis factor (STF), activated cells expressing TLR2.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c64 : 1
stoichiometry:c65 : 1
stoichiometry:c66 : 1
m3964*m32*0.1
nodelay
--
0
PMID: 16885502 The mycobacterial components, lipoarabinomannan (LAM) and soluble tuberculosis factor (STF), activated cells expressing TLR2.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c67 : 1
stoichiometry:c68 : 1
stoichiometry:c69 : 1
m183*m41*0.1
nodelay
--
0
PMID: 16885502, 10383454, 9734363, 11960013 IRAKs bind to TRAF6.
p25
p25
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c70 : 1
stoichiometry:c71 : 1
stoichiometry:c72 : 1
m1569*m183*0.1
nodelay
--
0
PMID: 16885502, 10383454, 9734363, 11960013 IRAKs bind to TRAF6.
p26
p26
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c73 : 1
stoichiometry:c74 : 1
stoichiometry:c75 : 1
m183*m17258*0.1
nodelay
--
0
PMID: 16885502, 10383454, 9734363, 11960013 IRAKs bind to TRAF6.
p27
p27
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c76 : 1
stoichiometry:c77 : 1
stoichiometry:c78 : 1
m1571*m183*0.1
nodelay
--
0
PMID: 16885502, 10383454, 9734363, 11960013 IRAKs bind to TRAF6.
p28
p28
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c95 : 1
stoichiometry:c96 : 1
stoichiometry:c97 : 1
stoichiometry:c98 : 1
m39*m1573*m6432*0.1
nodelay
--
0
PMID: 16885502, 14751757 Following phosphorylation of IRAK-1, IRAK-1 and TRAF-6 dissociate from the receptor complex, and TRAF-6 interacts with TGF-?-activated kinase-1 (TAK-1), TAK-1/2-binding protein, resulting in activation of TAK-1.
p29
p29
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c88 : 1
stoichiometry:c93 : 1
stoichiometry:c82 : 1
m17258*m35*0.1
nodelay
--
0
PMID: 16885502, 12055225 LPS causes IRAK-1 activation, phosphorylation, and subsequent degradation. PMID: 16885502, 11960013 IRAK-4 has been demonstrated to act upstream of IRAK-1 and is responsible for phosphorylation of IRAK-1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c7 : 1
stoichiometry:c8 : 1
stoichiometry:c6 : 1
m93309*m6*0.1
nodelay
--
0
PMID: 16885502 MALP-2 was found to induce self-tolerance as measured by TNF-{alpha} production but also, to induce cross-tolerance to LPS.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c79 : 1
stoichiometry:c81 : 1
stoichiometry:c80 : 1
m94019*0.1
nodelay
--
0
PMID: 16885502 When cells were pretreated with BLP for 24 h, there was a marked decrease in IRAK-1 protein levels compared with na?ve cells.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c106 : 1
stoichiometry:c107 : 1
m46*0.1
nodelay
--
0
PMID: 16885502 Following activation, NF-{kappa}B is translocated to the nucleus, where it activates the transcription of proinflammatory genes.
p32
p32
cso30:i:ME_Dissociation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c83 : 1
stoichiometry:c109 : 1
stoichiometry:c85 : 1
stoichiometry:c94 : 1
m42*0.1
nodelay
--
0
PMID: 16885502, 14751757 Following phosphorylation of IRAK-1, IRAK-1 and TRAF-6 dissociate from the receptor complex, and TRAF-6 interacts with TGF-?-activated kinase-1 (TAK-1), TAK-1/2-binding protein, resulting in activation of TAK-1. PMID: 16885502 IRAK-M prevents dissociation of IRAK-1 and IRAK-4 from MyD88 and inhibits formation of the IRAK-TRAF-6 complex.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c99 : 1
stoichiometry:c100 : 1
m22*0.1
nodelay
--
0
PMID: 16885502, 10602462 Activation of IKK complex results in phosphorylation of I{kappa}B{alpha} and I{kappa}Bbeta, ubiquitination, and degradation of I{kappa}B, and release of the active NF-{kappa}B complex.
p34
p34
cso30:i:ME_UnknownDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c101 : 1
stoichiometry:c86 : 1
stoichiometry:c87 : 1
m45*0.1
nodelay
--
0
PMID: 16885502, 10602462 Activation of IKK complex results in phosphorylation of I{kappa}B{alpha} and I{kappa}Bbeta, ubiquitination, and degradation of I{kappa}B, and release of the active NF-{kappa}B complex.
p35
p35
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c110 : 1
stoichiometry:c112 : 1
stoichiometry:c111 : 1
m554*m13*0.1
nodelay
--
0
PMID: 16885502, 12133836 BLP stimulation of THP-1 monocytes induces activation of ERK1/2, JNK, and p38.
p36
p36
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c113 : 1
stoichiometry:c115 : 1
stoichiometry:c114 : 1
m549*m13*0.1
nodelay
--
0
PMID: 16885502, 12133836 BLP stimulation of THP-1 monocytes induces activation of ERK1/2, JNK, and p38.
p37
p37
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c116 : 1
stoichiometry:c118 : 1
stoichiometry:c117 : 1
m25*m13*0.1
nodelay
--
0
PMID: 16885502, 12133836 BLP stimulation of THP-1 monocytes induces activation of ERK1/2, JNK, and p38.
p38
p38
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c119 : 1
stoichiometry:c121 : 1
stoichiometry:c120 : 1
m23*m13*0.1
nodelay
--
0
PMID: 16885502, 12133836 BLP stimulation of THP-1 monocytes induces activation of ERK1/2, JNK, and p38.
p4
p4
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c9 : 1
stoichiometry:c10 : 1
stoichiometry:c11 : 1
m2828*m155666*0.1
nodelay
--
0
PMID: 16885502, 1698311 CD14 recognizes and binds LPS with high-affinity.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c12 : 1
stoichiometry:c13 : 1
stoichiometry:c14 : 1
m2828*m12*0.1
nodelay
--
0
PMID: 16885502, 9605151, 10452971, 8675286 CD14 has also been implicated in activation of the inflammatory response to gram-positive bacterial components such as BLP and LTA.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c15 : 1
stoichiometry:c16 : 1
stoichiometry:c17 : 1
m14*m2828*0.1
nodelay
--
0
PMID: 16885502, 9605151, 10452971, 8675286 CD14 has also been implicated in activation of the inflammatory response to gram-positive bacterial components such as BLP and LTA.
p7
p7
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c18 : 1
stoichiometry:c19 : 1
stoichiometry:c20 : 1
stoichiometry:c21 : 1
m11*m3961*0.1
nodelay
--
0
PMID: 16885502, 11067937, 10725698 Multiple studies have confirmed that LPS signals primarily through TLR4.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c22 : 1
stoichiometry:c23 : 1
stoichiometry:c24 : 1
m16*m1572*0.1
nodelay
--
0
PMID: 16885502, 10754329, 10215628 After ligand binding, TLRs sequentially recruit the adaptor molecules MyD88, IL-1R-associated kinase (IRAK)and TNF receptor-associated factor 6 (TRAF6).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c25 : 1
stoichiometry:c26 : 1
stoichiometry:c27 : 1
m17*m184*0.1
nodelay
--
0
PMID: 16885502, 10754329, 10215628 After ligand binding, TLRs sequentially recruit the adaptor molecules MyD88, IL-1R-associated kinase (IRAK)and TNF receptor-associated factor 6 (TRAF6).
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--